InspireMD Inc. (NSPR) News
Filter NSPR News Items
NSPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NSPR News From Around the Web
Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.
InspireMD Reports Narrower Loss In Q2 As Revenue Rebounds On Procedural RecoveryInspireMD Inc (NASDAQ: NSPR ) has recorded a robust increase in second-quarter FY21 sales of $1.04 million, +231.6% Y/Y, slightly missing the consensus of $1.1 million. The Company posted a narrower EPS loss of $(0.46) compared to $(2.93) a year ago, beating the Full story available on Benzinga.com |
InspireMD Announces Strong Second Quarter 2021 Financial ResultsRevenue rebound, strong procedural recovery |
InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate UpdateEarnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET |
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPSTEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Companys U.S. registration C-Guardian trial of CGuard EPS. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
Should I Avoid InspireMD Inc (NSPR)?No summary available. |
InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ Tickers to be NSPRW and NSPRZ |
InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZInspireMD, Inc., developer of the CGuard Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market. |
InspireMD Announces Appointment of Katie Arnold to Board of DirectorsTEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology. “We are pleased to welcome Katie to the InspireMD Board. She is a proven marketing professional with a track record for delivering flawless launch execution and implementing key business strategies,” comme... |
InspireMD, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / May 11, 2021 / InspireMD, Inc. (AMEX:NSPR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 8:30 AM Eastern Time. |